Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 17 May 2012 | By Louise Zornoza,
The Chinese State Food and Drug Administration (SFDA) issued a Notice to Provinces, Autonomous Regions, and Municipalities on 16 May revising the instructions in the Chinese non-prescription drugs (OTC) manual related to the pediatric use requirements for amantadine hydrochloride compounds.
The compounds can no longer be used in newborns and children under one year of age due to a lack of safety and effectiveness data and are not recommended for children under the age of five. Drug manufacturers must amend labeling accordingly and local authorities must ensure timely reporting of adverse reactions.
SFDA - State Food and Drug Administration to amend the non-prescription drug instructions containing amantadine hydrochloride
More Breaking News from RegLink
Tags: State Food and Drug Administration, SFDA, regulation
Regulatory Focus newsletters
All the biggest regulatory news and happenings.